vs
碧迪（BDX）与SELECT MEDICAL HOLDINGS CORP（SEM）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是SELECT MEDICAL HOLDINGS CORP的3.8倍（$5.3B vs $1.4B）。碧迪净利率更高（7.3% vs 1.4%，领先5.8%）。SELECT MEDICAL HOLDINGS CORP同比增速更快（6.4% vs -0.4%）。碧迪自由现金流更多（$549.0M vs $5.2M）。过去两年SELECT MEDICAL HOLDINGS CORP的营收复合增速更高（2.8% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Select Medical是总部位于美国宾夕法尼亚州的医疗健康企业，业务涵盖长期急症护理、住院康复医院运营，同时开设有职业健康与物理治疗诊所，母公司Select Medical Holdings在纽约证券交易所挂牌上市。
BDX vs SEM — 直观对比
营收规模更大
BDX
是对方的3.8倍
$1.4B
营收增速更快
SEM
高出6.8%
-0.4%
净利率更高
BDX
高出5.8%
1.4%
自由现金流更多
BDX
多$543.8M
$5.2M
两年增速更快
SEM
近两年复合增速
2.0%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $1.4B |
| 净利润 | $382.0M | $20.2M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 4.6% |
| 净利率 | 7.3% | 1.4% |
| 营收同比 | -0.4% | 6.4% |
| 净利润同比 | 24.0% | 225.7% |
| 每股收益（稀释后） | $1.34 | $0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXSEM
| Q4 25 | $5.3B | $1.4B | ||
| Q3 25 | $5.9B | $1.4B | ||
| Q2 25 | $5.5B | $1.3B | ||
| Q1 25 | $5.3B | $1.4B | ||
| Q4 24 | $5.2B | $1.3B | ||
| Q3 24 | $5.4B | $1.3B | ||
| Q2 24 | $5.0B | $1.3B | ||
| Q1 24 | $5.0B | $1.3B |
净利润BDXSEM
| Q4 25 | $382.0M | $20.2M | ||
| Q3 25 | $493.0M | $28.8M | ||
| Q2 25 | $574.0M | $40.6M | ||
| Q1 25 | $308.0M | $56.7M | ||
| Q4 24 | $303.0M | $-16.1M | ||
| Q3 24 | $400.0M | $55.6M | ||
| Q2 24 | $487.0M | $77.6M | ||
| Q1 24 | $537.0M | $96.9M |
毛利率BDXSEM
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXSEM
| Q4 25 | 10.5% | 4.6% | ||
| Q3 25 | 11.8% | 5.4% | ||
| Q2 25 | 16.0% | 6.5% | ||
| Q1 25 | 10.4% | 8.3% | ||
| Q4 24 | 8.8% | 1.6% | ||
| Q3 24 | 11.4% | 4.3% | ||
| Q2 24 | 12.1% | 5.8% | ||
| Q1 24 | 14.5% | 9.0% |
净利率BDXSEM
| Q4 25 | 7.3% | 1.4% | ||
| Q3 25 | 8.4% | 2.1% | ||
| Q2 25 | 10.4% | 3.0% | ||
| Q1 25 | 5.8% | 4.2% | ||
| Q4 24 | 5.9% | -1.2% | ||
| Q3 24 | 7.4% | 4.4% | ||
| Q2 24 | 9.8% | 6.1% | ||
| Q1 24 | 10.6% | 7.3% |
每股收益（稀释后）BDXSEM
| Q4 25 | $1.34 | $0.17 | ||
| Q3 25 | $1.71 | $0.23 | ||
| Q2 25 | $2.00 | $0.32 | ||
| Q1 25 | $1.07 | $0.44 | ||
| Q4 24 | $1.04 | $-0.12 | ||
| Q3 24 | $1.37 | $0.43 | ||
| Q2 24 | $1.68 | $0.60 | ||
| Q1 24 | $1.85 | $0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $26.5M |
| 总债务越低越好 | — | $1.8B |
| 股东权益账面价值 | $25.3B | $1.7B |
| 总资产 | $54.8B | $5.9B |
| 负债/权益比越低杠杆越低 | — | 1.06× |
8季度趋势，按日历期对齐
现金及短期投资BDXSEM
| Q4 25 | $740.0M | $26.5M | ||
| Q3 25 | $641.0M | $60.1M | ||
| Q2 25 | $735.0M | $52.3M | ||
| Q1 25 | $667.0M | $53.2M | ||
| Q4 24 | $711.0M | $59.7M | ||
| Q3 24 | $1.7B | $191.5M | ||
| Q2 24 | $4.5B | $111.2M | ||
| Q1 24 | $2.3B | $92.6M |
总债务BDXSEM
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $1.8B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | — | $3.6B | ||
| Q1 24 | — | $3.8B |
股东权益BDXSEM
| Q4 25 | $25.3B | $1.7B | ||
| Q3 25 | $25.4B | $1.7B | ||
| Q2 25 | $25.5B | $1.7B | ||
| Q1 25 | $25.2B | $1.7B | ||
| Q4 24 | $25.2B | $1.7B | ||
| Q3 24 | $25.9B | $1.9B | ||
| Q2 24 | $25.9B | $1.4B | ||
| Q1 24 | $25.6B | $1.4B |
总资产BDXSEM
| Q4 25 | $54.8B | $5.9B | ||
| Q3 25 | $55.3B | $5.7B | ||
| Q2 25 | $54.9B | $5.7B | ||
| Q1 25 | $54.5B | $5.7B | ||
| Q4 24 | $54.7B | $5.6B | ||
| Q3 24 | $57.3B | $8.0B | ||
| Q2 24 | $55.6B | $7.9B | ||
| Q1 24 | $54.2B | $7.9B |
负债/权益比BDXSEM
| Q4 25 | — | 1.06× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.62× | ||
| Q2 24 | — | 2.54× | ||
| Q1 24 | — | 2.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $64.3M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $5.2M |
| 自由现金流率自由现金流/营收 | 10.5% | 0.4% |
| 资本支出强度资本支出/营收 | 2.1% | 4.2% |
| 现金转化率经营现金流/净利润 | 1.72× | 3.19× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $117.2M |
8季度趋势，按日历期对齐
经营现金流BDXSEM
| Q4 25 | $657.0M | $64.3M | ||
| Q3 25 | $1.4B | $175.3M | ||
| Q2 25 | $1.2B | $110.3M | ||
| Q1 25 | $164.0M | $-3.5M | ||
| Q4 24 | $693.0M | $125.4M | ||
| Q3 24 | $1.2B | $181.0M | ||
| Q2 24 | $1.3B | $278.2M | ||
| Q1 24 | $514.0M | $-66.7M |
自由现金流BDXSEM
| Q4 25 | $549.0M | $5.2M | ||
| Q3 25 | $1.0B | $122.2M | ||
| Q2 25 | $1.0B | $45.6M | ||
| Q1 25 | $35.0M | $-55.8M | ||
| Q4 24 | $588.0M | $62.0M | ||
| Q3 24 | $882.0M | $130.3M | ||
| Q2 24 | $1.1B | $222.6M | ||
| Q1 24 | $380.0M | $-119.2M |
自由现金流率BDXSEM
| Q4 25 | 10.5% | 0.4% | ||
| Q3 25 | 17.0% | 9.0% | ||
| Q2 25 | 19.0% | 3.4% | ||
| Q1 25 | 0.7% | -4.1% | ||
| Q4 24 | 11.4% | 4.7% | ||
| Q3 24 | 16.2% | 10.2% | ||
| Q2 24 | 22.4% | 17.4% | ||
| Q1 24 | 7.5% | -9.0% |
资本支出强度BDXSEM
| Q4 25 | 2.1% | 4.2% | ||
| Q3 25 | 6.0% | 3.9% | ||
| Q2 25 | 3.2% | 4.8% | ||
| Q1 25 | 2.4% | 3.9% | ||
| Q4 24 | 2.0% | 4.8% | ||
| Q3 24 | 5.4% | 4.0% | ||
| Q2 24 | 3.6% | 4.3% | ||
| Q1 24 | 2.7% | 4.0% |
现金转化率BDXSEM
| Q4 25 | 1.72× | 3.19× | ||
| Q3 25 | 2.75× | 6.09× | ||
| Q2 25 | 2.12× | 2.72× | ||
| Q1 25 | 0.53× | -0.06× | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | 2.94× | 3.25× | ||
| Q2 24 | 2.66× | 3.59× | ||
| Q1 24 | 0.96× | -0.69× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
SEM
| Critical Illness Recovery Hospitals | $629.7M | 45% |
| Health Care Patient Service Non Medicare | $428.6M | 31% |
| Rehabilitation Hospitals | $339.2M | 24% |
